Lead Sponsor

MetrioPharm AG

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Participant is admitted to hospital and has a positive severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) test by standard reverse transcription-polymerase chain reaction (RT-PCR) assay or equivalent test
•Participant has the presence of any symptom(s) suggestive of moderate or severe systemic illness with COVID-19

•Participant, in opinion of the investigator, is not likely to survive \>=48 hours beyond Day 1
•Participant has a diagnosis of asymptomatic COVID-19, mild COVID-19, or critical COVID-19 on Day 1
•Participant has a documented medical history of infection with hepatitis A, B, C, or with human immunodeficiency virus (with a detectable viral load and CD4 count \<500 cells per micro liter), or a documented active infection with tuberculosis.
•The Participant has clinically significant electrocardiogram (ECG) abnormalities at screening

Related studies

NCT01306084 · Anogenital Herpes, COVID-19, and more

NCT04551378 · COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, and more

NCT05218083 · COVID-19, Critical Illness, and more

NCT05078905 · COVID-19, Vaccination, and more

NCT07552779 · Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), and more

MP1032 Treatment in Patients With Moderate to Severe COVID-19